GAIN THERAPEUTICS, INC Payments to Acquire Marketable Securities
GAIN THERAPEUTICS, INC (GANX) reported Payments to Acquire Marketable Securities of $1.96 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-03-27
- GAIN THERAPEUTICS, INC payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- GAIN THERAPEUTICS, INC payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- GAIN THERAPEUTICS, INC payments to acquire marketable securities for the quarter ending 2023-06-30 was $0.00.
- GAIN THERAPEUTICS, INC payments to acquire marketable securities for the quarter ending 2023-03-31 was $1.96M.
- GAIN THERAPEUTICS, INC payments to acquire marketable securities for fiscal 2023 was $1.96M, a 88.97% decline from fiscal 2022.
- GAIN THERAPEUTICS, INC payments to acquire marketable securities for fiscal 2022 was $17.74M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $1.96M 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $1.96M 10-Q · filed 2024-11-14 | $3.89M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.96M 10-Q · filed 2024-08-08 | $3.89M derived: sum of 3 quarters · filed 2024-08-08 | $4.85M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.96M 10-Q · filed 2024-05-14 | $3.89M derived: sum of 2 quarters · filed 2024-05-14 | $4.85M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $2.89M derived: sum of 2 quarters · filed 2024-03-26 | $17.74M 10-K · filed 2024-03-26 | |
| 2022-09-30 | $959.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $15.80M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $14.84M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |